Premium
Reversible mechlorethamine‐associated hearing loss in a patient with hodgkin's disease
Author(s) -
Segal Gerald M.,
Duckert Larry G.
Publication year - 1986
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19860315)57:6<1089::aid-cncr2820570603>3.0.co;2-r
Subject(s) - medicine , hearing loss , disease , audiology
Mechlorethamine, when administered in massive doses (0.6–1.5 mg/kg) to cancer patients in several early studies, caused severe irreversible hearing loss. There have been no reports of ototoxicity with doses of 0.4 mg/kg or less. The authors describe a 36‐year‐old man who developed profound sensorineural hearing loss during his first cycle of MOPP chemotherapy for Hodgkin's disease. Cyclophosphamide was substituted for mechlorethamine in subsequent cycles and his hearing deficit resolved. This is the first reported case of reversible ototoxicity associated with currently recommended doses of mechlorethamine.